Jaguar Health (NASDAQ:JAGX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Jaguar Health (NASDAQ:JAGX) in a report released on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Jaguar Health Stock Down 7.2 %

Shares of JAGX opened at $0.23 on Thursday. The company has a current ratio of 1.84, a quick ratio of 1.36 and a debt-to-equity ratio of 1.65. Jaguar Health has a one year low of $0.20 and a one year high of $21.60. The stock has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.96.

Institutional Trading of Jaguar Health

An institutional investor recently bought a new position in Jaguar Health stock. Virtu Financial LLC bought a new stake in Jaguar Health, Inc. (NASDAQ:JAGX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned approximately 0.22% of Jaguar Health as of its most recent SEC filing. Hedge funds and other institutional investors own 12.04% of the company’s stock.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.